The Effects of Exenatide After Gastric Restriction
NCT00872378 on ClinicalTrials.gov · last registry update 2009-03-31
A small phase 2/phase 3 — 28 participants, against a typical 60. Its estimated completion date, December 2010, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P2/P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Advanced Specialty Care
- Sponsor type
- Other
- Enrollment
- 28
- Started
- 2009-02
- Primary completion
- 2010-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide plus lifestyle modification plan or placebo plus lifestyle modification plan.
Conditions studied
Morbid Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.